Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1997 Oct;88(10):992–1002. doi: 10.1111/j.1349-7006.1997.tb00320.x

Antitumor Activity of a Novel Quinoline Derivative, TAS‐103, with Inhibitory Effects on Topoisomerases I and II

Teruhiro Utsugi 1, Kumio Aoyagi 1, Tetsuji Asao 1, Shinji Okazaki 1, Yoshimi Aoyagi 1, Masaki Sano 1, Konstanty Wierzba 1, Yuji Yamada 1
PMCID: PMC5921285  PMID: 9414662

Abstract

A novel quinoline derivative, TAS‐103 (6‐[[2‐(dimethyIamino)ethyl]amino]‐3‐hydroxy‐7H‐indeno[2,l‐c]quinolin‐7‐one dihydrochloride), was developed as an anticancer agent targeting topoisomerases (topo) I and II, with marked efficacy in solid tumors. TAS‐103 inhibited topo I and II (IC50: 2 μM, 6.5 μM) at a concentration similar to or lower than those of previous agents, and had a strong cytotoxic effect on P388 and KB cells (IC50,: 0.0011 μM, 0.0096 μM). TAS‐103 stabilized topo I and II‐DNA cleavable complexes in KB cells, generating a similar amount of topo II‐DNA complex to that induced by etoposide (VP‐16) but a smaller amount of topo I‐DNA complex than that produced by camptothecin (CPT). In the in vivo study, intermittent i.v. administration was markedly effective against s.c.‐implanted murine tumors. Furthermore, TAS‐103 had marked efficacy against various lung metastatic tumors, and a broad antitumor spectrum in human tumor xenografts (derived from lung, colon, stomach, breast, and pancreatic cancer). The efficacy of TAS‐103 was generally greater than that of irinotecan (CPT‐11), VP‐16, or cis‐diamminedichloroplatinum (CDDP).

Keywords: TAS‐103, Quinoline derivative, Antitumor activity, Topoisomerase I, Topoisomerase II

Full Text

The Full Text of this article is available as a PDF (617.7 KB).

REFERENCES

  • 1. ) Wang , J. C.DNA topoisomerases . Annu. Rev. Biochem. , 65 , 635 – 692 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Osheroff , N.Biochemical basis for the interactions of type I and type II topoisomerases with DNA . Pharmacol. Ther. , 41 , 223 – 241 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Davies , S. M. , Robson , C. N. , Davies , S. L. and Hickson , I. D.Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins . J.Biol, Chem. , 263 , 17724 – 17729 ( 1988. ). [PubMed] [Google Scholar]
  • 4. ) Deffie , A. M. , Batra , J. K. and Goldenberg , G. J.Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin‐sensitive and ‐resistant P388 leukemia cell lines . Cancer Res. , 49 , 58 – 62 ( 1989. ). [PubMed] [Google Scholar]
  • 5. ) Bjornsti , M.‐A. , Benedetti , P. , Viglianti , G. A. and Wang , J. C.Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin . Cancer Res. , 49 , 6318 – 6323 ( 1989. ). [PubMed] [Google Scholar]
  • 6. ) Heck , M. M. S. , Hittelman , W. N. and Earnshaw , W. C.Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle . Proc. Natl Acad. Sci. USA , 85 , 1086 – 1090 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. ) Chow , K.‐C. and Ross , W. E.Topoisomerase‐specific drug sensitivity in relation to cell cycle progression . Mol. Cell. Biol , 7 , 3119 – 3123 ( 1987. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. ) Giovanella , B. C. , Stehlin , J. S. , Wall , M. E. , Wani , M. C. , Nicholas , A. W. , Liu , L. F. , Silber , R. and Potmesil , M.DNA topoisomerase I‐targeted chemotherapy of human coloncancer in xenografts . Science , 246 , 1046 – 1048 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) van der Zee , A. G. J. , Hollema , H. , de Jong , S. , Boonstra , H. , Gouw , A. , Willemse , P. H. B. , Zijlstra , J. G. and de Vries , E. G. E.P‐Glycoprotein expression and DNA topoisomerase I and II activity in benign tumor of the ovary and in malignant tumor of the ovary, before and after platinum/cyclophosphamide chemotherapy . Cancer Res. , 51 , 5915 – 5920 ( 1991. ). [PubMed] [Google Scholar]
  • 10. ) Potmesil , M. , Hsiang , Y.‐H. , Liu , L. F. , Bank , B. , Grossberg , H. , Kirschenbaum , S. , Forlenzar , T. J. , Penziner , A. , Kanganis , D. , Knowles , D. , Traganos , F. and Silber , R.Resistance of human leukemic and normal lymphocytes to drug‐induced DNA cleavage and low levels of DNA topoisomerase II . Cancer Res. , 48 , 3537 – 3543 ( 1988. ). [PubMed] [Google Scholar]
  • 11. ) Holden , J. A. , Rolfson , D. H. and Wittwer , C. T.Human DNA topoisomerase II: evaluation of enzyme activity in normal and neoplastic tissues . Biochemistry , 29 , 2127 – 2134 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 12. ) Husain , I. , Mohler , J. L. , Seigler , H. F. and Besterman , J. M.Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumor: demonstration of tumor‐type specificity and implications for cancer chemotherapy . Cancer Res. , 54 , 539 – 546 ( 1994. ). [PubMed] [Google Scholar]
  • 13. ) Beck , W. T. , Cirtain , M. C. , Danks , M. K. , Felsted , R. L. , Safa , A. R. , Wolverton , J. S. , Suttle , D. P. and Trent , J. M.Pharmacological, molecular, and cytogenetic analysis of “atypical” multidrug‐resistant human leukemic cells . Cancer Res. , 47 , 5455 – 5460 ( 1987. ). [PubMed] [Google Scholar]
  • 14. ) Danks , M. K. , Schmidt , C. A. , Cirtain , M. C. , Suttle , D. P. and Beck , W. T.Altered catalytic activity of and DNA cleavage by BNA topoisomerase II from human leukemia cells selected for resistance to VM‐26 . Biochemistry , 21 , 8861 – 8869 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Tan , K. B. , Mattern , M. R. , Eng , W.‐K. , McCabe , F. L. and Johnson , R. K.Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors . J. Natl, Cancer Inst , 81 , 1732 – 1735 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Sugimoto , Y. , Tsukahara , S. , Oh‐hara , T. , Liu , L. F. and Tsuruo , T.Elevated expression of DNA topoisomerase II in camptothecin‐resistant human tumor cell lines . Cancer Res. , 50 , 7962 – 7965 ( 1990. ). [PubMed] [Google Scholar]
  • 17. ) Riou , J.‐F. , Helissey , P. , Grondard , L. and Giorgi‐Renault , S.Inhibition of eukaryotic DNA topoisomerase I and II activities by indoloquinolinedione derivatives . Mol. Pharmacol , 40 , 699 – 706 ( 1991. ). [PubMed] [Google Scholar]
  • 18. ) Yamashita , Y. , Kawada , S. , Fujii , N. and Nakano , H.Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus . Biochemistry , 30 , 5838 – 5845 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 19. ) Larsen , A. K. , Grondard , L. , Couprie , J. , Desoize , B. , Comoe , L. , Jardillier , J.‐C. and Riou , J.‐F.The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II . Biochem. Pharmcol. , 46 , 1403 – 1412 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 20. ) Poddevin , B. , Riou , J.‐F. , Lavelle , F. and Pommier , Y.Dual topoisomerase I and II inhibition by intoplicine (RP‐60475), a new antitumor agent in early clinical trials . Mol. Pharmacol , 44 , 767 – 774 ( 1993. ). [PubMed] [Google Scholar]
  • 21. ) Utsugi , T. , Mattern , M. R. , Mirabelli , C. K. and Hanna , N.Potentiation of topoisomerase inhibitor‐induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation . Cancer Res. , 50 , 2636 – 2640 ( 1990. ). [PubMed] [Google Scholar]
  • 22. ) Utsugi , T. , Shibata , J. , Sugimoto , Y. , Aoyagi , K. , Wierzba , K. , Kobunai , T. , Terada , T. , Oh‐hara , T. , Tsuruo , T. and Yamada , Y.Antitumor activity of a novel podophyllotoxin derivative (TOP‐53) against lung cancer and lung metastatic cancer . Cancer Res. , 56 , 2809 – 2814 ( 1996. ). [PubMed] [Google Scholar]
  • 23. ) Trask , D. K. and Muller , M. T.Stabilization of type I topoisomerase‐DNA covalent complexes by actinomycin D . Proc. Natl. Acad. Sci. USA , 85 , 1417 – 1421 ( 1988. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. ) Labarca , C. and Paigen , K.A simple, rapid, sensitive DNAassay procedure . Anal.Biochem. , 102 , 344 – 352 ( 1980. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Inaba , M. , Kobayashi , T. , Tashiro , T. , Sakurai , Y. , Maruo , K. , Ohnishi , Y. , Ueyama , Y. and Nomura , T.Evaluation of antitumor activity in a human breast tumor/ nude mouse model with a special emphasis on treatment dose . Cancer , 64 , 1577 – 1582 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Inaba , M.Pharmacokinetic approach to the improvement of clinical predictability in the preclinical test for anti‐tumor agents . Jpn. J. Cancer Chemother. , 18 , 1449 – 1456 ( 1991. ). [PubMed] [Google Scholar]
  • 27. ) Marcus , R. , Peritz , E. and Gabriel , K. R.On closed testing procedures with special reference to ordered analysis of variance . Biometrika , 63 , 655 – 660 ( 1976. ). [Google Scholar]
  • 28. ) Hochberg , Y.A sharper Bonferroni procedure for multiple tests of significance . Biometrika , 75 , 800 – 802 ( 1988. ). [Google Scholar]
  • 29. ) Zwelling , L. A. , Hinds , M. , Chan , D. , Mayes , J. , Sie , K. L. , Parker , E. , Silberman , L. , Radciffe , A. , Beran , M. and Blick , M.Characterization of an amsacrine‐resistant line of human leukemia cells. Evidence for a drug‐resistant form of topoisomerase II . J. Biol Chem. , 264 , 16411 – 16420 ( 1989. ). [PubMed] [Google Scholar]
  • 30. ) Kunimoto , T. , Nitta , K. , Tanaka , T. , Uehara , N. , Baba , H. , Takeuchi , M. , Yokokura , T. , Sawada , S. , Miyasaka , T. and Mutai , M.Antitumor activity of 7‐ethyl‐10‐[4‐(1 ‐piperidino) ‐1 ‐piperidino] carbonyloxy‐camptothecin, a novel water‐soluble derivative of camptothecin, against murine tumors . Cancer Res. , 47 , 5944 – 5947 ( 1987. ). [PubMed] [Google Scholar]
  • 31. ) Jensen , P.B. , Roed , H. , Skovsgaard , T. , Friche , E. , Vindelov , L. , Hansen , H. H. and Spang‐Thomsen , M.Antitumor activity of the two epipodophyllotoxin derivatives VP‐16 and VM‐26 in preclinical systems: a comparisonof invitro andinvivo drugevaluation . Cancer Chemother. Pharmacol , 27 , 194 – 198 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 32. ) Staroselsky , A. M. , Fan , D. , O'Brian , C. A. , Bucana , C. D. , Gupta , K. P. and Fidler , I. J.Site‐dependent differences in response of the UV‐2237 murine fibrosarcoma to systemic therapy with adriamycin . Cancer Res. , 50 , 7775 – 7780 ( 1990. ). [PubMed] [Google Scholar]
  • 33. ) Wilmanns , C. , Fan , D. , O'Brian , C. A. , Bucana , C. D. and Fidler , I. J.Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5‐fluorouracil . Int. J. Cancer , 52 , 98 – 104 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 34. ) Mattern , J. , Bak , M. , Hahn , E. W. and Volm , M.Human tumor xenograftsas models for drug testing . Cancer Metastasis Rev. , 7 , 263 – 284 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 35. ) Liu , L. F.DNA topoisomerase poisons as antitumor drugs . Annu. Rev. Biochetn. , 58 , 351 – 375 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 36. ) Tanabe , K. , Ikegami , Y. , Ishida , R. and Andoh , T.Inhibition of topoisomerase II by antitumor agents bis (2,6‐dioxopiperazine) derivatives . Cancer Res. , 51 , 4903 – 4908 ( 1991. ). [PubMed] [Google Scholar]
  • 37. ) Tewey , K. M. , Rowe , T. C. , Yang , L. , Halligan , B. D. and Liu , L. F.Adriamycin‐induced DNA damage mediated by mammalian DNA topoisomerase II . Science , 226 , 466 – 468 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 38. ) Nelson , E. M. , Tewey , K. M. and Liu , L. F.Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II by 4′‐(9‐acridinylamino)methanesulfon‐m‐anisidide . Proc. Natl. Acad. Sci.USA , 81 , 1361 – 1365 ( 1984. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. ) Jensen , P. B. , Sorensen , B. S. , Demant , E. J. F. , Sehested , M. , Jensen , P. S. , Vindelov , L. and Hansen , H. H.Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′‐(acridinylamino)methanesulfon‐m‐amisidide in human small cell lung cancer cell lines and on topoisomerase II‐mediated DNA cleavage . Cancer Res. , 50 , 3311 – 3316 ( 1990. ). [PubMed] [Google Scholar]
  • 40. ) Fukuoka , M. , Niitani , H. , Suzuki , A. , Motomiya , M. , Hasegawa , K. , Nishiwaki , Y. , Kuriyama , T. , Ariyoshi , Y. , Negoro , S. , Masuda , N. , Nakajima , S. and Taguchi , T.A phase II study of CPT‐11, a new derivative of camptothecin, for previously untreated non‐small‐cell lung cancer . J. Clin. Oncol , 10 , 16 – 20 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 41. ) Strauss , G. , Pagani , O. , Sessa , C. , Lund , B. , Cavalli , F. and Hansen , H. H.A phase I study of intoplicine (RP60475F, NSC D 645008) administered on a daily × 5 schedule . Proc. Am. Assoc. Cancer Res. , 34 , A1378 ( 1993. ). [Google Scholar]
  • 42. ) Utsugi , T. , Aoyagi , K. , Furune , Y. , Sano , M. , Wierzba , K. , Okazaki , S. , Asao , T. and Yamada , Y.Antitumor activity of T AS‐103, a novel topoisomerase I and II inhibitor . Proc. Am. Assoc. Cancer Res. , 37 , 2915 ( 1996. ). [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES